Serotonergic neurotoxicity of 3,4-(±)-methylenedioxyamphetamine and 3,4-(±)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of γ-glutamyl transpeptidase

Chemical Research in Toxicology

Volumn 14, Issue 7, 2001, Pages 863-870

  Bai, F ^a,b   Jones, D C ^a   Lau, S S ^a   Monks, T J ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; ACIVICIN; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN CORTEX; BRAIN REGION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG POTENTIATION; ENZYME INHIBITION; HIPPOCAMPUS; HYPOTHALAMUS; MALE; NEUROTOXICITY; NONHUMAN; RAT; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; VASCULAR ENDOTHELIUM;

3,4-METHYLENEDIOXYAMPHETAMINE; ADMINISTRATION, CUTANEOUS; ANIMALS; BRAIN; ENDOTHELIUM; ENZYME INHIBITORS; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; ISOXAZOLES; MALE; MODELS, MOLECULAR; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXICITY SYNDROMES; NEUROTRANSMITTER AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGENTS;

EID: 0034933347     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx010011l     Document Type: Article

References (41)

1. Memory impairment in abstinent MDMA ("Ecstasy") users
2. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings
3. Human research on MDMA (3,4-Methylene-dioxymethamphetamine) neurotoxicity: Cognitive and behavioural indices of change
4. Toxic effects of MDMA on central serotonergic neurons in the primate: Importance of route and frequency of drug administration
5. Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy')
6. Direct intracerebral administration of MDA and MDMA does not produce serotonin neurotoxicity
7. Direct central effects of acute methylenedioxy-methamphetamine on serotonergic neurons
8. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA)
9. Influence of inducers and inhibitors on the metabolism in vitro and neurochemical effects in vivo of MDMA
10. Major metabolites of (±)-3,4-methylenedioxy-amphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons
11. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl]propane[(methylenedioxy) methamphet-amine]
12. Long-term alteration in the central monaminergic systems of the rat by 2,4,5-trihydroxyamphetamine, but not by 2-hydroxy-4,5-methylenedioxymetamphetamine or 2-hydroxy-4,5-methyl-enedioxyamphetamine
13. Effect of 5-(Glutathion-S-yl)-α-methyl-dopamine on dopamine, serotonin and norepinephrine concentrations following intracerebroventricular administration to male Spragne-Dawley rats
14. 2,5-bis-(Glutathion-S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations
15. Glutathione and N-acetylcysteine conjugates of α-methyldopamine produce serotonergic neurotoxicity. Possible role in methylenedioxy-amphetamine-mediated neurotoxicity
16. Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Spragne - Dawley rats
17. Glutathione and related γ-glutamyl compounds. Biosynthesis and utilization
18. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy')
19. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain
20. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine
21. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
22. Microglial response to brain injury: A brief synopsis
23. Reactive microgliosis
24. Animal behavioral and neurochemical effects of the CNS toxic amino acid antitumor agent, acivicin
25. Carrier-mediated transport of the antitumor agent acivicin across the blood-brain barrier
26. Biological reactivity of polyphenolic-glutathione conjugates
27. Amino acid assignment to one of three blood-brain barrier amino acid carriers
28. Mutagenicity of dichloroacetylene and its degradation products trichloroacetyl chloride, trichloroacryloyl chloride and hexachlorobutadiene
29. Carcinogenicity of dichloroacetylene: An inhalation study
30. Brain uptake of S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine, the glutathione and cysteine S-conjugates of the neurotoxin dichloroacetylene
31. The pharmacology and toxicology of polyphenolic-glutathione conjugates
32. Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat
33. GSH transport in immortalized mouse brain endothelial cells: Evidence for apical localization of a sodium-dependent GSH transporter
34. +-dependent GSH transport in HCEC
35. Transport of glutathione at blood-brain barrier of the rat: Inhibition by glutathione analogs and age-dependence
36. Effect of inhibition of γ-glutamyl transpeptidase by AT-125 (acivicin) on glutathione and cysteine levels in rat brain and plasma
37. Renal clearance of glutathione measured in rats pretreated with inhibitors of glutathione metabolism
38. Role of quinones in toxicology
39. Brain mitochondria catalyze the oxidation of 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to intermediates that irreversibly inhibit complex I and scavenge glutathione: Potential relevance to the pathogenesis of Parkinson's disease
40. Oxidative metabolites of 5-S-cysteinylnorepinephrine are irreversible inhibitors of mitochondrial complex I and the alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes: Possible implications for neurodegenerative brain disorders
41. Putative oxidative metabolites of 1-methyl-6-hydroxy-1,2,3,4-tetrahydro-β-carboline of potential relevance to the addictive and neurodegenerative consequences of ethanol abuse